News / Taiwan / economic_daily
Handa Pharma Reports July EPS of NT$0.02, TTM EPS Reaches NT$3.08
Health Technology · Pharmaceuticals: Major · economic_daily · 2026-09-09
6620
Handa Pharmaceuticals disclosed its latest financial results following a stock price surge, highlighting a July EPS of NT$0.02 and a strong TTM performance driven by recent FDA approval.
What Happened
Financial Disclosure: Handa Pharmaceuticals released its July financial data at the request of the Taipei Exchange, reporting revenue of NT$72 million and a net profit of NT$4 million. The monthly EPS of NT$0.02 reflects a decline compared to the previous year, highlighting short-term operational volatility.
Drug Development Success: The company recently received final FDA approval for its self-developed cancer drug, HND-039. This milestone is significant given the drug's substantial market potential in the United States, providing a major catalyst for future growth.
Market Performance: Driven by the positive news regarding the FDA approval, Handa's stock price has rallied significantly since early September, peaking at NT$132. Investors have reacted enthusiastically to the company's improved competitive positioning.
Long-term Profitability: Despite the monthly fluctuations, the company's performance over the last four quarters remains solid, with a cumulative EPS of NT$3.08. This underscores the underlying strength of Handa's business model as it transitions into a new phase of commercialization.